Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia characterized by the proliferation of promyelocytes. It is associated with the presence of the promyelocytic leukemia-retinoic acid receptor alpha (PML-RARA) fusion gene, often resulting from a translocation between chromosomes 15 and 17. The condition is clinically significant due to its unique treatment response to all-trans retinoic acid (ATRA) and arsenic trioxide, which can lead to remission. The ICD-10 code C92.41 facilitates accurate diagnosis, documentation, medical billing, and public health reporting, ensuring appropriate care and resource allocation.
ICD-10 Code C92.41 specifically denotes Acute promyelocytic leukemia that is currently in remission. This condition arises from the accumulation of promyelocytes in the bone marrow and is often linked to the PML-RARA fusion gene. This code should be utilized in clinical documentation and billing when a patient has achieved remission following treatment, indicating a positive response to therapy and the need for continued monitoring.
Acute promyelocytic leukemia, in remission, is a hematological malignancy that requires prompt medical intervention. It is characterized by the rapid proliferation of promyelocytes and is often associated with coagulopathy. The condition necessitates ongoing monitoring and management to prevent relapse.
ICD-10 Code C92.41 is utilized in SOAP notes to document the patient's remission status, guiding clinical assessments and treatment plans. It plays a crucial role in both acute and chronic care settings, ensuring comprehensive documentation of the patient's condition and treatment response.
In SOAP notes, ICD-10 Code C92.41 connects subjective reports of symptoms and objective clinical findings to a formal diagnosis of Acute promyelocytic leukemia in remission. This code is essential for ensuring continuity of care, supporting accurate billing, and meeting EHR documentation standards.
Management of Acute promyelocytic leukemia in remission focuses on maintaining remission and preventing relapse. Treatment strategies are tailored to the individual patient's needs.


HIPAA-compliant and designed with privacy in mind, your patient’s data is protected. Focus on care while we safeguard your information.
Learn moreICD-10 Code C92.41 is crucial for accurate billing in hospital, ER, or infectious disease care settings.
| CPT Code | Description |
|---|---|
| 85025 | Complete blood count with differential. |
| 85027 | Complete blood count with automated differential. |
| 88305 | Pathology examination of bone marrow. |
| 96413 | Chemotherapy administration, intravenous. |
Common Questions About Using ICD-10 Code C92.41 for Acute promyelocytic leukemia, in remission
What does it mean for Acute promyelocytic leukemia to be in remission?
Remission in Acute promyelocytic leukemia indicates that the signs and symptoms of the disease have significantly decreased or are no longer detectable, often following effective treatment. Regular monitoring is essential to ensure that the disease does not relapse.
How is Acute promyelocytic leukemia treated?
Acute promyelocytic leukemia is primarily treated with all-trans retinoic acid (ATRA) and arsenic trioxide. These treatments target the underlying genetic abnormalities and can lead to remission in many patients.
What are the common symptoms of Acute promyelocytic leukemia?
Common symptoms include fatigue, fever, easy bruising or bleeding, and frequent infections. These symptoms arise from the bone marrow's inability to produce healthy blood cells due to the proliferation of promyelocytes.
Why is follow-up important after achieving remission?
Follow-up is crucial after achieving remission to monitor for potential relapse and manage any long-term effects of treatment. Regular blood tests and clinical evaluations help ensure ongoing health and timely intervention if needed.
Clinical Notes
SOAP notes
DAP notes
AI medical notes